Literature DB >> 22836176

Serotonin-1A receptor binding is positively associated with gray matter volume -- a multimodal neuroimaging study combining PET and structural MRI.

Christoph Kraus1, Andreas Hahn, Markus Savli, Georg S Kranz, Pia Baldinger, Anna Höflich, Christoph Spindelegger, Johanna Ungersboeck, Daniela Haeusler, Markus Mitterhauser, Christian Windischberger, Wolfgang Wadsak, Siegfried Kasper, Rupert Lanzenberger.   

Abstract

Animal models revealed that the serotonin-1A (5-HT(1A)) receptor modulates gray matter structure. However, there is a lack of evidence showing the relationship between 5-HT(1A) receptor concentration and gray matter in the human brain in vivo. Here, to demonstrate an association between the 5-HT(1A) receptor binding potential, an index for receptor concentration, and the local gray matter volume (GMV), an index for gray matter structure, we measured 35 healthy subjects with both positron emission tomography (PET) and structural magnetic resonance imaging (MRI). We found that regional heteroreceptor binding was positively associated with GMV in distinctive brain regions such as the hippocampi and the temporal cortices in both hemispheres (R(2) values ranged from 0.308 to 0.503, p<0.05 cluster-level FDR-corrected). Furthermore, autoreceptor binding in the midbrain raphe region was positively associated with GMV in forebrain projection sites (R(2)=0.656, p=0.001). We also observed a broad range between 5-HT(1A) receptor binding and GMV. Given the congruence of altered 5-HT(1A) receptor concentrations and GMV reduction in depression or Alzheimer's disease as reported by numerous studies, these results might provide new insights towards understanding the mechanisms behind GMV alterations observed in these brain disorders.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836176     DOI: 10.1016/j.neuroimage.2012.07.035

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  8 in total

1.  Adult neuroplasticity: A new “cure” for major depression?

Authors:  Paul R. Albert
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

2.  [MedUni Wien researcher of the month, November 2012].

Authors:  Andreas Hahn
Journal:  Wien Klin Wochenschr       Date:  2012-11       Impact factor: 1.704

3.  Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity?

Authors:  Rajapillai L I Pillai; Mengru Zhang; Jie Yang; Maura Boldrini; J John Mann; Maria A Oquendo; Ramin V Parsey; Christine DeLorenzo
Journal:  Depress Anxiety       Date:  2018-01-24       Impact factor: 6.505

4.  NRM 2021 Abstract Booklet.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2021-12       Impact factor: 6.960

5.  Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data.

Authors:  Douglas N Greve; Claus Svarer; Patrick M Fisher; Ling Feng; Adam E Hansen; William Baare; Bruce Rosen; Bruce Fischl; Gitte M Knudsen
Journal:  Neuroimage       Date:  2013-12-19       Impact factor: 6.556

6.  Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study.

Authors:  Rajapillai L I Pillai; Ashwin Malhotra; Deborah D Rupert; Bennett Weschler; John C Williams; Mengru Zhang; Jie Yang; J John Mann; Maria A Oquendo; Ramin V Parsey; Christine DeLorenzo
Journal:  Hum Brain Mapp       Date:  2017-11-27       Impact factor: 5.038

7.  Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging.

Authors:  Pia Baldinger; Anna S Höflich; Markus Mitterhauser; Andreas Hahn; Christina Rami-Mark; Marie Spies; Wolfgang Wadsak; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety.

Authors:  Lauri Nummenmaa; Tomi Karjalainen; Janne Isojärvi; Tatu Kantonen; Jouni Tuisku; Valtteri Kaasinen; Juho Joutsa; Pirjo Nuutila; Kari Kalliokoski; Jussi Hirvonen; Jarmo Hietala; Juha Rinne
Journal:  Neuropsychopharmacology       Date:  2020-05-30       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.